Group 1 - The core point of the article is that Xige Biotechnology (Shenzhen) Co., Ltd. has recently completed an A-round financing of 80 million RMB to accelerate the global clinical development of its "organoid + AI" innovative drug pipeline [1] - Xige Biotechnology was established in 2020 and is located in Shenzhen, focusing on research and experimental development [1] - The company has a registered capital of 1.69084205 million RMB and has completed its A-round financing by 2026, with a transaction amount of 80 million RMB [1] Group 2 - The company holds 21 trademark registrations and 13 patents, along with 10 administrative licenses [1] - The shareholders of Xige Biotechnology include Shenzhen Xige New Research Biotechnology Partnership, Zhang Haisheng, Shenzhen Xige Inno Biotechnology Partnership, XtalPi Investment Limited, and Shenzhen Tiantuo Xing Shen Angel Investment Partnership [1]
希格生科（深圳）有限公司获“A轮”融资，金额8000万人民币
Sou Hu Cai Jing·2026-01-14 05:26